Elafibranor not checked

Ipsen · GFT505 · IPN60190

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 3 trial completes
Trials
5 active
9 in total · 5 in the EU
Targets
 

What this is

How it works
Peroxisome Proliferator-activated Receptor Agonist FDA class
How it’s given
“Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which elafibranor 80 mg tablet will be administered once daily”In the company’s words, NCT06016842 on ClinicalTrials.gov
Tested for
Primary Sclerosing Cholangitis (2 trials), Primary Biliary Cirrhosis, Primary Biliary Cholangitis, Primary Biliary Cholangitis (PBC)
Main trialPhase 3
“The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (which is a medication used in the management and treatment of cholestatic liver disease). PBC is a slowly progressive disease characterized by damage of the bile ducts in the liver, leading to a buildup of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and…”In the company’s words, NCT04526665 on ClinicalTrials.gov
Other names
GFT505 · IPN60190 · Iqirvo

Other drugs for Primary Sclerosing Cholangitis

All 7 drugs for Primary Sclerosing Cholangitis

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 1 Jun 2023 Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
Phase 3Active, not recruiting 17 Dec 2026 A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
Phase 3Recruiting 31 May 2029 A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
Phase 3Recruiting 30 Apr 2031 A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
Phase 2Active, not recruiting 23 Sep 2031 A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
Phase 3Completed 16 Jun 2026 A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
Phase 2Completed Feb 2015 Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Phase 1Completed 30 Dec 2022 A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants After Intake of a Single Tablet
Phase 1Completed 10 Mar 2023 Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Elafibranor

Following is part of Solo: you see every change to Elafibranor the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in